- Home
- JAZZ vs DCI Comparison
JAZZ vs DCI Comparison
Compare JAZZ & DCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JAZZ | DCI |
|---|---|---|
| Founded | 2003 | 1915 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Pollution Control Equipment |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.4B | 10.5B |
| IPO Year | 2007 | 1987 |
Fundamental Metrics
Financial Performance| Metric | JAZZ | DCI |
|---|---|---|
| Price | $168.86 | $101.16 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 16 | 5 |
| Target Price | ★ $207.19 | $98.00 |
| AVG Volume (30 Days) | ★ 1.1M | 643.5K |
| Earning Date | 02-24-2026 | 02-26-2026 |
| Dividend Yield | N/A | ★ 1.19% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 3.21 |
| Revenue | ★ $4,157,832,999.00 | $3,726,200,000.00 |
| Revenue This Year | $6.00 | $4.61 |
| Revenue Next Year | $6.35 | $4.58 |
| P/E Ratio | ★ N/A | $31.42 |
| Revenue Growth | ★ 4.14 | 2.37 |
| 52 Week Low | $95.49 | $57.45 |
| 52 Week High | $182.99 | $100.91 |
Technical Indicators
Market Signals| Indicator | JAZZ | DCI |
|---|---|---|
| Relative Strength Index (RSI) | 53.50 | 76.25 |
| Support Level | $159.35 | $94.22 |
| Resistance Level | $173.09 | $96.08 |
| Average True Range (ATR) | 5.80 | 1.60 |
| MACD | -0.29 | 0.93 |
| Stochastic Oscillator | 65.44 | 98.55 |
Price Performance
Historical ComparisonAbout JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
About DCI Donaldson Company Inc.
Donaldson is a leading manufacturer of filtration systems and replacement parts (including air filtration systems, liquid filtration systems, and dust, fume, and mist collectors). The company serves a diverse range of end markets, including construction, mining, agriculture, truck, and industrial. Its business is organized into three segments: mobile solutions, industrial solutions, and life sciences. Donaldson generated approximately $3.7 billion in revenue in its fiscal 2025.